Horizon Pharma (HZNP) Tops Q3 EPS by 4c, Beats on Revenues; Boosts FY17 Revenue & EBITDA Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Horizon Pharma (HZNP) Tops Q3 EPS by 4c, Beats on Revenues; Boosts FY17 Revenue & EBITDA Outlook
November 7, 2017 8:34 AM EST
Jefferies raised its price target on Horizon Pharma (NASDAQ: HZNP) to $21.00 (from $16.00) while maintaining a Buy rating following the company's 3Q earnings report.
Including the upside from the Q3 results and expected shift in operating expenses from Q3 to Q4, Jefferies raised... More
November 3, 2017 11:02 AM EDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today presented a post-hoc analysis of data from two randomized, placebo-controlled clinical trials of KRYSTEXXA® (pegloticase injection) in adults living with chronic gout refractory to conventional therapies, also known as uncontrolled gout. In the post-hoc analysis, nearly two-thirds of patients who were serum uric acid (sUA) responders to KRYSTEXXA experienced reductions in mean arterial blood pressure (MAP) throughout the trials. The analysis (Pegloticase, a Mammalian Uricase,... More
